Management of Beta-Hemolytic Streptococci (Non-Group A)
Do not treat beta-hemolytic streptococci that are not confirmed to be Group A streptococcus, as only Group A streptococcus causes the complications (acute rheumatic fever, suppurative complications) that justify antibiotic therapy. 1
Critical Distinction: Beta-Hemolytic Does Not Equal Group A
The presence of beta-hemolytic colonies on culture is insufficient for treatment because multiple beta-hemolytic streptococci exist beyond Group A, including:
These non-Group A beta-hemolytic streptococci have different clinical significance and do not cause acute rheumatic fever or the suppurative complications that are the primary justification for antibiotic treatment in pharyngitis. 1
Required Laboratory Confirmation
Proper identification requires specific grouping through:
- Latex agglutination testing for Group A carbohydrate antigen
- Immunofluorescence
- Definitive serological grouping methods 1
Group A streptococci are beta-hemolytic, but not all beta-hemolytic streptococci are Group A—this is the critical laboratory distinction that must be made before initiating therapy. 1
Treatment Algorithm
If Group A Streptococcus is NOT Confirmed:
- Discontinue antibiotics if already started empirically 1
- The CDC advises against initiating antibiotics until Group A streptococcus is specifically confirmed, as empiric treatment of non-GAS pharyngitis leads to unnecessary antibiotic exposure, adverse effects, and antimicrobial resistance without preventing any complications 1
- Do not perform routine testing or treatment of asymptomatic household contacts 3, 4
If Group A Streptococcus IS Confirmed:
- Penicillin V 500 mg orally twice daily for 10 days remains the treatment of choice 4, 3, 1
- Intramuscular benzathine penicillin G is preferred for patients unlikely to complete oral therapy 4
- For penicillin-allergic patients (non-anaphylactic): first-generation cephalosporins 4, 3
- For anaphylactic penicillin allergy: azithromycin 12 mg/kg once daily (maximum 500 mg) for 5 days, though macrolides should be avoided in areas with high resistance rates 1
Common Pitfalls to Avoid
The most critical error is treating beta-hemolytic colonies without confirming Group A status. This leads to:
- Unnecessary antibiotic exposure without clinical benefit 1
- Increased antimicrobial resistance 1
- Potential adverse drug effects 4, 3
- No prevention of complications, as non-Group A beta-hemolytic streptococci do not cause acute rheumatic fever 1
Clinical diagnosis alone has insufficient accuracy (≤80% predictive value even with scoring systems), making microbiologic confirmation with specific Group A identification essential before initiating antibiotics. 1
When to Consider Treatment Despite Non-Group A Result
The IDSA recommends antimicrobial therapy may be initiated while laboratory confirmation is pending in cases of high clinical suspicion, provided therapy is discontinued if Group A streptococcus is not confirmed. 1 However, this should be the exception rather than the rule, reserved for patients with:
- Severe clinical presentation
- High risk for complications
- Inability to follow up for culture results 1